Chris Boshoff/LinkedIn
May 31, 2025, 18:35
Chris Boshoff: BREAKWATER Study Halves Risk of Death in BRAF V600E-Mutated Metastatic Colorectal Cancer
Chris Boshoff, Chief Scientific Officer and President of Research and Development at Pfizer, shared a post on LinkedIn:
“Today at ASCO25 and simultaneously published in NEJM Group, Pfizer shared pivotal overall survival and progression-free survival data for a targeted treatment regimen in patients with metastatic Colorectal Cancer (mCRC) with a BRAF V600E mutation.
For about 1 in 5 people diagnosed with CRC, the disease has already metastasized by the time it’s detected – making treatment more complex.
The BREAKWATER study met its primary endpoint of progression-free survival, as well as a key secondary endpoint of overall survival, showing that the regimen halved the risk of death for people with mCRC with a BRAF V600E mutation. These exciting results support its potential to be a new standard-of-care and a meaningful advance for these patients.”
Proceed to the video attached to the post.
More posts featuring Chris Boshoff.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 31, 2025, 17:48
May 31, 2025, 17:47
May 31, 2025, 17:39
May 31, 2025, 17:38
May 31, 2025, 15:43